Key Insights on Jazz Pharmaceuticals Stock

Mid-cap Health Care company Jazz Pharmaceuticals has logged a -8.0% change today on a trading volume of 1,515,934. The average volume for the stock is 568,645.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company is now trading -36.8% away from its average analyst target price of $188.83 per share. The 18 analysts following the stock have set target prices ranging from $135.0 to $235.0, and on average give Jazz Pharmaceuticals a rating of buy.

Over the last 12 months JAZZ shares have declined by -10.1%, which represents a difference of -37.5% when compared to the S&P 500. The stock's 52 week high is $147.98 per share and its 52 week low is $111.25. With its net margins declining an average -33.3% over the last 6 years, Jazz Pharmaceuticals declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 3,794,392 79,954 2 133.33
2022 3,659,374 -224,060 -6 45.45
2021 3,094,238 -329,668 -11 -210.0
2020 2,363,567 238,616 10 -58.33
2019 2,161,761 523,367 24 0.0
2018 1,890,922 447,098 24 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.